P
Paulus Kirchhof
Researcher at University of Birmingham
Publications - 659
Citations - 119822
Paulus Kirchhof is an academic researcher from University of Birmingham. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 100, co-authored 558 publications receiving 106459 citations. Previous affiliations of Paulus Kirchhof include United States Department of Veterans Affairs & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Gone Fishing (for Silent Atrial Fibrillation)
Yousif Ahmad,Paulus Kirchhof +1 more
TL;DR: Atrial fibrillation is associated with a stubbornly elevated mortality and treatment of other acute and chronic cardiac disorders that predispose to AF will further prolong the lives of patients at risk of AF.
Journal ArticleDOI
Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint.
TL;DR: The currently available evidence on dual antiplatelet therapy and oral anticoagulation is summarized and the key questions that remain to be answered are highlighted including ongoing clinical trials in the field.
Journal ArticleDOI
Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern
Lars Eckardt,T. Deneke,Hans-Christoph Diener,Gerd Hindricks,H. M. Hoffmeister,Stefan H. Hohnloser,Paulus Kirchhof,Paulus Kirchhof,C. Stellbrink +8 more
TL;DR: The European Society of Cardiology has issued new AF guidelines, which have a clinical focus on stroke prevention as well as rate and rhythm control and summarize current evidence-based therapy.
Journal ArticleDOI
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
B. Schrage,B. Schrage,Benedikt N Beer,Gianluigi Savarese,Salim Dabboura,Isabell Yan,Jonas Sundermeyer,Peter Moritz Becher,Hanno Grahn,Moritz Seiffert,Alexander M. Bernhardt,Holger Thiele,Jacob E. Møller,Stefan Kluge,Hermann Reichenspurner,Paulus Kirchhof,Stefan Blankenberg,Dirk Westermann +17 more
TL;DR: In this paper, the authors investigated the eligibility of MCS patients in randomised controlled trials (RCTs) and found that only 31.8% of the patients were eligible for any study and the lowest eligibility was observed for DanGer-SHOCK (11.9%) and the highest for IABP-ShOCK II (26.9%).
Journal ArticleDOI
Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.
Andreas Metzner,Anna Suling,Axel Brandes,Axel Brandes,Günter Breithardt,A. John Camm,Harry J.G.M. Crijns,Lars Eckardt,Arif Elvan,Andreas Goette,Laurent M. Haegeli,Hein Heidbuchel,Josef Kautzner,Karl-Heinz Kuck,Luis Mont,A Andre Ng,Lukasz Szumowski,Sakis Themistoclakis,Isabelle C. Van Gelder,Panos E. Vardas,Karl Wegscheider,Stephan Willems,Paulus Kirchhof +22 more
TL;DR: In EAST-AFNET 4, the clinical benefit of early, systematic rhythm control therapy was achieved using variable treatment patterns of antiarrhythmic drugs and atrial fibrillation ablation, applied within guideline recommendations as mentioned in this paper.